Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

BioCryst Pharmaceuticals

Thumbnail
March 01, 2021

US FDA approval tracker February

Thumbnail
February 22, 2021

Biocryst looks to raise the profile of its factor D inhibitor

The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.

Article image
Vantage logo
January 22, 2021

Apellis takes the complement fight to Astrazeneca

The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.

Article image
Vantage logo
January 06, 2021

US FDA approval tracker: December

Article image
Vantage logo
December 18, 2020

First-quarter catalysts for the smaller players

Important data releases are on the cards for Rhythm, Wave and Supernus, among others.

Article image
Vantage logo
November 27, 2020

Go or no go? The year ends with Covid-19 vaccine approvals in sight

December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.

Article image
Vantage logo
October 09, 2020

Veklury confirms its modest benefit as Merck's antiviral advances

Article image
Vantage logo
March 19, 2020

Hope replaces hype for coronavirus stocks

Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.

Article image
Vantage logo
March 18, 2020

A Covid-19 treatment plan slowly emerges

Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.

Article image
Vantage logo
March 05, 2020

Previous pandemic antiviral demand spike sees Biocryst jump aboard

Article image
Vantage logo
March 05, 2020

Biopharma’s role in tackling coronavirus

The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.